Patient and graft characteristics of low DC and high DC patient groups
Characteristics . | Low DC group; n = 23 . | High DC group; n = 27 . |
|---|---|---|
| Patients | ||
| Recipient male, % | 60.9 | 55.6 |
| Donor male, % | 39.1 | 40.7 |
| Recipient age, y | 45.6 ± 10.5 | 44.8 ± 14.4 |
| Donor age, y | 46.0 ± 12.0 | 43.8 ± 16.6 |
| Transplantation | ||
| Myeloablative, % | 82.6 | 63.0 |
| High disease risk, %* | 87.0 | 85.2 |
| Donor CMV+, % | 52.2 | 70.4 |
| Patient DC count before, median (range, lower to upper quartiles)† | 5.8 (4.4-15.6) | 10.1 (6.5-14.9) |
| Graft source | ||
| Peripheral blood stem cells, no. of patients | 23 | 23 |
| Bone marrow, no. of patients | 0 | 4 |
| Graft | ||
| CD34+ infused, × 106/kg | 5.6 ± 1.9 | 5.3 ± 2.1 |
| CD3+ infused, × 108/kg‡ | 3.1 ± 2.2 | 2.4 ± 1.8 |
| DCs infused, × 106/kg§ | 7.6 ± 5.5 | 7.1 ± 4.6 |
| Engraftment parameters | ||
| White blood cell count, 1 × 109/L | 5.6 ± 6.4 | 6.0 ± 7.6 |
| Median ANC, 1 × 109/L (mean ± SD) | 1.95 (4.2 ± 4.0) | 3.47 (4.2 ± 6.1) |
| CD3+ cells, 1 × 109/L | 0.47 ± 0.60 | 0.54 ± 0.64 |
Characteristics . | Low DC group; n = 23 . | High DC group; n = 27 . |
|---|---|---|
| Patients | ||
| Recipient male, % | 60.9 | 55.6 |
| Donor male, % | 39.1 | 40.7 |
| Recipient age, y | 45.6 ± 10.5 | 44.8 ± 14.4 |
| Donor age, y | 46.0 ± 12.0 | 43.8 ± 16.6 |
| Transplantation | ||
| Myeloablative, % | 82.6 | 63.0 |
| High disease risk, %* | 87.0 | 85.2 |
| Donor CMV+, % | 52.2 | 70.4 |
| Patient DC count before, median (range, lower to upper quartiles)† | 5.8 (4.4-15.6) | 10.1 (6.5-14.9) |
| Graft source | ||
| Peripheral blood stem cells, no. of patients | 23 | 23 |
| Bone marrow, no. of patients | 0 | 4 |
| Graft | ||
| CD34+ infused, × 106/kg | 5.6 ± 1.9 | 5.3 ± 2.1 |
| CD3+ infused, × 108/kg‡ | 3.1 ± 2.2 | 2.4 ± 1.8 |
| DCs infused, × 106/kg§ | 7.6 ± 5.5 | 7.1 ± 4.6 |
| Engraftment parameters | ||
| White blood cell count, 1 × 109/L | 5.6 ± 6.4 | 6.0 ± 7.6 |
| Median ANC, 1 × 109/L (mean ± SD) | 1.95 (4.2 ± 4.0) | 3.47 (4.2 ± 6.1) |
| CD3+ cells, 1 × 109/L | 0.47 ± 0.60 | 0.54 ± 0.64 |
Unless otherwise indicated, values are mean ± SD.
High disease risk: acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) other than first complete remission (CR1), primary induction failure; acute leukemia from antecedent hematologic disorder; chronic myelogenous leukemia not in first chronic phase (CML not CP1); chronic lymphocytic leukemia (CLL); acute bilineage leukemia (ABIL); non-Hodgkin lymphoma (NHL); Hodgkin disease (HD); myelodysplastic syndrome (MDS) not refractory anemia (RA) or ringed sideroblasts (RARS); multiple myeloma (MM); eosinophilic leukemia (n = 1). Low disease risk: ALL CR1; AML CR1; CML CP1; MDS RA, RARS.
Known for 47 of 50 patients who underwent transplantation.
Known for 49 of 50 patients who underwent transplantation.
Known for 32 of 50 patients who underwent transplantation.